IPF Cough: Opioid-Based Approach Tested
Researchers examine oral nalbuphine for chronic cough in IPF, using objective digital monitoring and patient-reported measures.
-
By
-
Kathryn Wighton
-
January 28, 2026
-
Clinical Scorecard: IPF Cough: Opioid-Based Approach Tested
At a Glance
| Category | Detail |
|---|
| Condition | Idiopathic Pulmonary Fibrosis (IPF) with Chronic Cough |
| Key Mechanisms | Oral κ-opioid receptor agonist (nalbuphine) targeting cough frequency |
| Target Population | Adults with IPF and chronic cough lasting at least 8 weeks |
| Care Setting | Multinational, randomized, double-blind, placebo-controlled clinical trial |
Key Highlights
- Dose-dependent reductions in cough frequency observed with nalbuphine
- 60% reduction in cough frequency with 108 mg dose at 6 weeks
- Improvements in cough severity and quality of life in higher dose groups
- Study involved 165 patients across 52 sites in 10 countries
- Common adverse events included nausea, vomiting, and dizziness
Guideline-Based Recommendations
Diagnosis
- Cough severity numerical rating scale score of 4 or higher
- Prespecified pulmonary function criteria must be met
Management
- Consider nalbuphine extended release for chronic cough in IPF patients
Monitoring & Follow-up
- Continuous digital cough monitoring for 24 hours to assess cough frequency
Risks
- Mild adverse events primarily during dose titration, potential for bias in missing data
Patient & Prescribing Data
Median age 71 years, 72% male, 77% on antifibrotic therapy
Effective cough frequency reduction observed with higher nalbuphine doses
Clinical Best Practices
- Monitor patients for adverse events during dose titration
- Assess patient-reported outcomes alongside objective cough measurements
- Consider long-term efficacy and safety in future studies
References
